Avanos Medical, Inc. (AVNS)
NYSE: AVNS · Real-Time Price · USD
25.03
+0.03 (0.12%)
Jun 9, 2026, 4:00 PM EDT - Market closed
Avanos Medical Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -74.4 | -72.9 | -392.1 | -61.8 | 50.5 | 6.3 |
Depreciation & Amortization | 39.5 | 38.9 | 45.5 | 46.1 | 47.7 | 38.3 |
Stock-Based Compensation | 12.5 | 12.6 | 13.8 | 15.8 | 15.9 | 13.2 |
Other Adjustments | 91.6 | 86.3 | 437.9 | 72.7 | 1.1 | 8 |
Change in Receivables | 5.5 | 30.9 | -6.6 | 39 | -24.7 | -10.8 |
Changes in Inventories | 5.1 | 0.2 | 39 | 4.7 | -30.9 | 15.7 |
Changes in Accounts Payable | 4.9 | 0.6 | -0.9 | -14.4 | 35.4 | -11.9 |
Changes in Accrued Expenses | -31.8 | -12.9 | -11.4 | -27.7 | -7.1 | 33.4 |
Changes in Other Operating Activities | 4 | -9 | -24.5 | -42 | 3 | -4.9 |
Operating Cash Flow | 36.7 | 74.7 | 100.7 | 32.4 | 90.9 | 87.3 |
Operating Cash Flow Growth | -72.69% | -25.82% | 210.80% | -64.36% | 4.12% | - |
Capital Expenditures | -29.2 | -31.6 | -17.8 | -17.8 | -19.3 | -21 |
Sale of Property, Plant & Equipment | 4 | 4 | - | - | - | - |
Payments for Business Acquisitions | -28 | -28 | - | -49.6 | -116.1 | - |
Proceeds from Business Divestments | - | - | 2.1 | 89 | - | - |
Other Investing Activities | -6 | -5 | -11.8 | - | - | - |
Investing Cash Flow | -59.2 | -60.6 | -27.5 | 21.6 | -135.4 | -21 |
Short-Term Debt Issued | - | - | 20 | 55 | 150 | 20 |
Short-Term Debt Repaid | - | -25 | -45 | -115 | -170 | -70 |
Net Short-Term Debt Issued (Repaid) | - | -25 | -25 | -60 | -20 | -50 |
Long-Term Debt Issued | - | - | - | - | 250 | - |
Long-Term Debt Repaid | -9.4 | -9.4 | -8.6 | -4.7 | -126.6 | - |
Net Long-Term Debt Issued (Repaid) | -9.4 | -9.4 | -8.6 | -4.7 | 123.4 | - |
Issuance of Common Stock | 0.7 | 0.7 | 1.1 | 1.3 | 1.7 | 6.2 |
Repurchase of Common Stock | -2.4 | -3.3 | -12.8 | -19.1 | -45.5 | -11.5 |
Net Common Stock Issued (Repurchased) | -1.7 | -2.6 | -11.7 | -17.8 | -43.8 | -5.3 |
Other Financing Activities | - | - | -3.8 | -11.7 | -2.9 | - |
Financing Cash Flow | -11.1 | -37 | -49.1 | -94.2 | 56.7 | -55.3 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 2.2 | 5 | -4.1 | 0.2 | -3 | -4 |
Net Cash Flow | -31.4 | -17.9 | 20 | -40 | 9.2 | 7 |
Free Cash Flow | 7.5 | 43.1 | 82.9 | 14.6 | 71.6 | 66.3 |
Free Cash Flow Growth | -82.60% | -48.01% | 467.81% | -79.61% | 7.99% | - |
FCF Margin | 1.05% | 6.15% | 12.05% | 2.17% | 10.47% | 11.29% |
Free Cash Flow Per Share | 0.16 | 0.93 | 1.80 | 0.31 | 1.51 | 1.36 |
Levered Free Cash Flow | 67.7 | 24.7 | 388.4 | -54 | 81.7 | -6.7 |
Unlevered Free Cash Flow | -73.82 | -81.63 | -349.6 | -45.84 | 57.39 | 20.98 |